• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Robert J. Hennessey appointed Nanotherapeutics chairman of the board

Robert J. Hennessey appointed Nanotherapeutics chairman of the board

June 26, 2017
CenterWatch Staff

Nanotherapeutics, a biologics-focused contract development and manufacturing organization (CDMO), announced that Robert J. Hennessey has been appointed chairman of the board.

Commenting on the announcement, Peter H. Khoury, Ph.D., president and chief executive officer of Nanotherapeutics, stated, “We are pleased to welcome Bob as chairman of the board. As a shareholder for the past 15 years and as a past board member, we have benefited greatly from Bob’s expertise, including his 25 years’ experience serving at large pharmaceutical companies. We anticipate more fully leveraging his insights and knowledge, specifically within health care corporate strategy, deal-making, financings and strategic alliances.”

“As Nanotherapeutics continues to grow and expand its global footprint, I am delighted to accept the new role and responsibilities of Chairman of the Board and look forward to helping guide the Company in the achievement of its strategic vision,” noted Mr. Hennessey.

Hennessey currently serves as chief executive officer of Mitotherapeutix, a privately-held biotechnology company he founded in 2014. The company is focused on the development of novel therapies for the treatment of diseases that can be targeted by modifying or influencing metabolic pathways in the cell, with a current focus on liver disease, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

Prior to founding Mitotherapeutix, Hennessey was Chairman of the board and business consultant to Genome Therapeutics (formerly known as Collaborative Research), where he also held the position of chief executive officer. During his tenure, Hennessey successfully restructured Collaborative Research into a drug discovery and genomics company through the execution of several key pharmaceutical alliances, and increased the company’s market capitalization from $15 million to more than $1.5 billion.

Before that, Hennessey was an Independent Consultant and Principal at Hennessey & Associates, specializing in the structuring of unencumbered strategic alliances between biotechnology and major pharmaceutical companies. Clients included Aventis (now Sanofi-Aventis), Genentech, Mannkind, Nycomed-Amersham, Pharmacyclics and others.

Prior to Hennessey & Associates, Hennessey was senior vice president of Corporate Development for Sterling Drug and also served as director, International Strategic Planning and Business Development for Abbott Laboratories. Earlier in his career, Hennessey held a number of positions with SmithKline, working on corporate strategy and managing the vaccines, biologics and diagnostics business in Europe.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing